UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from D. Boral Capital

UroGen Pharma (NASDAQ:URGN - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at D. Boral Capital in a research report issued on Thursday,Benzinga reports. They currently have a $25.00 target price on the stock. D. Boral Capital's target price points to a potential upside of 107.42% from the stock's current price.

Other research analysts have also recently issued research reports about the company. LADENBURG THALM/SH SH started coverage on UroGen Pharma in a research report on Wednesday, February 19th. They set a "buy" rating and a $31.00 target price on the stock. HC Wainwright lowered shares of UroGen Pharma from a "buy" rating to a "neutral" rating in a research note on Thursday, May 22nd. Guggenheim lowered their target price on shares of UroGen Pharma from $40.00 to $15.00 and set a "buy" rating for the company in a report on Friday, May 23rd. Scotiabank assumed coverage on shares of UroGen Pharma in a research report on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 price objective for the company. Finally, The Goldman Sachs Group cut their target price on UroGen Pharma from $16.00 to $3.00 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, UroGen Pharma presently has a consensus rating of "Moderate Buy" and an average target price of $23.14.

UroGen Pharma Trading Up 8.8%

NASDAQ URGN traded up $0.97 on Thursday, hitting $12.05. The company's stock had a trading volume of 4,054,350 shares, compared to its average volume of 959,609. The firm has a market cap of $555.73 million, a PE ratio of -3.92 and a beta of 0.40. UroGen Pharma has a 1-year low of $3.42 and a 1-year high of $20.70. The company's 50-day moving average is $8.49 and its 200 day moving average is $10.07. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The company had revenue of $20.25 million for the quarter, compared to analyst estimates of $22.71 million. As a group, analysts predict that UroGen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other UroGen Pharma news, insider Mark Schoenberg sold 5,162 shares of UroGen Pharma stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $7.37, for a total transaction of $38,043.94. Following the completion of the sale, the insider now owns 153,378 shares of the company's stock, valued at $1,130,395.86. The trade was a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On UroGen Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC bought a new stake in shares of UroGen Pharma during the fourth quarter valued at approximately $1,472,000. Lazard Asset Management LLC bought a new stake in shares of UroGen Pharma during the 4th quarter valued at about $67,000. Janus Henderson Group PLC bought a new position in UroGen Pharma in the fourth quarter worth approximately $149,000. ProShare Advisors LLC bought a new position in UroGen Pharma in the 4th quarter worth $137,000. Finally, Bank of New York Mellon Corp lifted its position in shares of UroGen Pharma by 7.3% during the 4th quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company's stock valued at $1,001,000 after buying an additional 6,430 shares in the last quarter. Institutional investors own 91.29% of the company's stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.